West Pharmaceutical Services, I (WST) currently reads Overbought on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Medical Instruments & Supplies) last closed at $352.79. The rating moved from Neutral to Overbought on August 19, 2026.

• Public ratingOverbought (as of August 19, 2026)
• Last close$352.79
• Last changeMoved from Neutral to Overbought on August 19, 2026
• SectorHealthcare
• IndustryMedical Instruments & Supplies

See all overbought Healthcare stocks →

AI analysis

West Pharmaceutical Services is well positioned as a specialist supplier to injectable and biologics manufacturers, with durable, volume-driven revenue and technical product barriers that support long-term customer relationships. Current market themes — including stronger demand for biologics, gene therapies and CDMO/fill-finish capacity — are constructive for addressable demand. Key near-term determinants include execution on capacity expansion, maintaining quality and customer qualification timelines, and how broader growth/valuation sentiment for biologics suppliers evolves. Limited social sentiment and absent fresh filings in the provided window increase reliance on sector readthroughs and operational execution for short-term performance.

Key factors

• Direct exposure to biologics and injectable drug-delivery supply chain benefiting from sustained demand for GLP-1, gene therapies, and advanced biologics
• Established OEM relationships and technical breadth across stoppers, seals, delivery systems and components that support high-barrier switching for customers
• Recurring, volume-driven revenue profile tied to long product lifecycles and regulatory-qualified components that support predictable cash flow
• Able to capture CDMO/CRO fill/finish and analytical testing tailwinds as biopharma commercialization expands
• Defensive cash-generation characteristics vs. pure biotech peers, providing flexibility for reinvestment or shareholder returns

Risks

• Customer concentration and contract dependence on a limited set of large pharmaceutical/biotech customers
• Operational and capacity execution risk: disruptions, quality issues, or failure to scale capacity for viral-vector/advanced biologics could dent revenue and margins
• Pricing pressure and competitive dynamics from other component suppliers or integrated CDMOs
• Valuation sensitivity: elevated multiples can amplify downside if demand for biologics growth moderates
• Regulatory, quality, or supply-chain events (raw-material constraints, inspection findings) that could interrupt shipments or increase costs

Latest MarketMoodz coverage

• Investors Await Damage Assessment After West Cyberattack2026-05-12

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.